Categories: Coronavirus

WHO Lists Ninth COVID-19 Vaccine For Emergency Use

This file photo taken on April 20, 2021 shows an empty vial of the Moderna Covid-19 vaccine among empty vials of different other vaccines by Pfizer-BioNTech (Comirnaty) and AstraZeneca at the vaccination center in Rosenheim, southern Germany, amid the novel coronavirus / COVID-19 pandemic.  Christof STACHE / AFP


The World Health Organization (WHO) on Friday issued an emergency use listing (EUL) for NVX-CoV2373, expanding the basket of WHO-validated vaccines against the SARS-CoV-2 virus.

The vaccine, named CovovaxTM, is produced by the Serum Institute of India under licence from Novavax and is part of the COVAX facility portfolio, giving a much-needed boost to ongoing efforts to vaccinate more people in lower-income countries.

WHO’s EUL procedure assesses the quality, safety, and efficacy of COVID-19 vaccines and is a prerequisite for COVAX vaccine supply. It also allows countries to expedite their own regulatory approval to import and administer COVID-19 vaccines.

READ ALSO: Again, Nigeria’s Daily COVID-19 Infections Exceed 1,000

“Even with new variants emerging, vaccines remain one of the most effective tools to protect people against serious illness and death from SARS-COV-2,” said Dr. Mariângela Simão, WHO Assistant-Director General for Access to Medicines and Health Products. ‘This listing aims to increase access particularly in lower-income countries, 41 of which have still not been able to vaccinate 10% of their populations, while 98 countries have not reached 40%.”

CovovaxTM was assessed under the WHO EUL procedure based on the review of data on quality, safety, and efficacy, a risk management plan, programmatic suitability, and manufacturing site inspections carried out by the Drugs Controller General of India.

The Technical Advisory Group for Emergency Use Listing (TAG-EUL), convened by WHO and made up of experts from around the world, has determined that the vaccine meets WHO standards for protection against COVID-19, that the benefit of the vaccine far outweighs any risks, and that the vaccine can be used globally.

CovovaxTM is a subunit of the vaccine developed by Novavax and the Coalition for Epidemic Preparedness Innovations (CEPI). It requires two doses and is stable at 2 to 8 °C refrigerated temperatures. The vaccine uses a novel platform and is produced by creating an engineered baculovirus containing a gene for a modified SARS-CoV-2 spike protein.

The originator product produced by Novavax, named NuvaxovidTM, is currently under assessment by the European Medicines Agency (EMA). WHO will complete its own assessment of this vaccine once the EMA has issued its recommendation.

A meeting of WHO’s Strategic Advisory Group of Experts on Immunization (SAGE) this week also reviewed the vaccine. SAGE formulates specific policies and recommendations for vaccines’ use in populations (i.e. recommended age groups, intervals between doses, specific groups such as pregnant and lactating women) and will issue recommendations for NuvaxovidTM/CovovaxTM in the coming days.

WHO emergency use listing

The emergency use listing (EUL) procedure assesses the suitability of novel health products during public health emergencies. The objective is to make medicines, vaccines, and diagnostics available as rapidly as possible to address the emergency while adhering to stringent criteria of safety, efficacy, and quality.

According to the WHO, the assessment weighs the threat posed by the emergency as well as the benefit that would accrue from the use of the product against any potential risks.

The EUL pathway involves a rigorous assessment of late phase II and phase III clinical trial data, as well as substantial additional data on safety, efficacy, quality, and a risk management plan.

These data are reviewed by independent experts and WHO teams who consider the current body of evidence on the vaccine under consideration, the plans for monitoring its use, and plans for further studies.

As part of the EUL process, the company producing the vaccine must commit to continue to generate data to enable full licensure and WHO prequalification of the vaccine.

The WHO prequalification process will assess additional clinical data generated from vaccine trials and deployment on a rolling basis to ensure the vaccine meets the necessary standards of quality, safety, and efficacy for broader availability.

Solomon Elusoji

Disqus Comments Loading...
Published by
Solomon Elusoji
Tags: COVID-19 Vaccine WHO

Recent Posts

  • Local

Ngige Optimistic Planned NLC Strike Won’t Hold 

The union had vowed to protest following the cash crunch in the country that has lasted over one month. 

6 mins ago
  • Local

Imo Assembly Lawmaker Egwim Dies After Illness

The deceased was a ranking member in the state house of assembly having been elected in 2015 and got re-elected…

31 mins ago
  • Local

Senate President: Senator Sani Musa Declares Interest

He is also asking the APC to address the issue of religious balancing in the zoning of seats for principal…

43 mins ago
  • Headlines

Amnesty International Raises Alarm Over ‘Thousands Killed’, Other Violations In Nigeria

Amnesty said the ICC's actions begged the question of whether its principles applied equally to victims of crimes under international…

1 hour ago
  • World News

Huddled In Giant Refrigerator, Nine Lives Saved From US Tornado

"It was so scary," the 52-year-old said, still trembling as she remembered the howling wind, flashes of lightening and pouring…

1 hour ago
  • Entertainment

Plaintiff Says Gwyneth Paltrow Ski Crash Changed His ‘Essence’

Asked about an email he sent to his daughters about the crash with a Hollywood celebrity with the subject line…

1 hour ago